- Joined
- Jul 14, 2020
- Messages
- 1,374
- Reaction score
- 4,156
The biggest part of the problem is intrinsic. To the outside world, we are by definition purveyors of a single drug, radiation. In an ever expanding therapeutic space with ever more nuanced ways of determining therapeutic need, we will of course become more and more marginalized. Combine this with the appropriate concern that we overtreat localized cancers that may or may not pose a significant risk to survival or QOL, and all meaningful pressures on radiation utilization in cancer are downward.I would love to hear strategies to how you think radonc can improve as a field. I dont believing shrink residency programs solves the whole problem. I think we need innovation and transformation to get with the times. If we keep doing the same thing as we have done for decades, we will get phased out and I think that is what many of you are seeing. Change though must come from us. No one will do it for us. I promise.
Unfortunately, I think that the best way that radonc can improve as a field may be devastating to early-to-mid career community doctors like myself and may also undermine the relative prominence of academic radoncs within their respective work space. That is, while focusing on the intrinsic strengths of traditional radiation oncology training (effectively administering radiation to fight cancer, understanding of sectional anatomy, patterns of failure, the relative importance of local control and consideration of competing risks when considering therapeutic escalation), find a way to integrate radonc into a more holistic national model for solid cancer oncology that includes training in systemic therapeutics.
This may require clear eyed restructuring of academic departments. It would require radical changes in training paradigm.
It would also be nice if academic leadership considered accreditation and practical training models for established community or clinical academic radiation oncologists to expand the scope of their practice into non-radio therapies and general outpatient management of low acuity, solid tumor patients. (This in and of itself could be a huge, short interval win for the main reason we are ranked low in health care metrics despite exceptional high-end technical care. Our distribution of care is poor.